ClinicalTrials.gg
CompletedNCT04035135Updated Aug 11, 2021

A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)

A Phase 1 interventional study of ANX005 and Intravenous immunoglobulin in Guillain-Barré Syndrome, sponsored by Annexon, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-11.

Sponsored by Annexon, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2021, 5 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a multi center, open-label, study of ANX005 in combination with IVIg in subjects diagnosed with GBS.

Read the detailed description

The study will enroll approximately 12 subjects into one cohort, with subjects receiving 75 mg/kg of ANX005, a dose shown to be safe and well-tolerated as monotherapy and that provides a meaningful level of exposure to be tested in combination with IVIg. Dosing of IVIg will be administered as is the current standard of care (0.4 g/kg/day x 5 days) and ANX005 will be administered concurrently, beginning on Day 1 or 2 of the treatment period. Subjects will be followed for 6 months after treatment for observation and evaluation.

02

Conditions studied

  • Guillain-Barré Syndrome
03

In context

Guillain-Barre Syndrome

98 studies on the registry are indexed under Guillain-Barre Syndrome; 30 are open to participants now.

This study's enrollment of 14 is below the median of 50 across 44 interventional studies indexed under Guillain-Barre Syndrome.

Browse Guillain-Barre Syndrome studies →

Lead sponsor

Annexon, Inc. is the lead sponsor of 16 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for Guillain Barré Syndrome
  • Onset of GBS-related weakness ≤14 days prior to infusion
  • GBS-DS score of 3, 4, or 5

Exclusion criteria

Exclusion Criteria:

  • findings that may interfere with the conduct of the study or the interpretation of the data
  • Be at risk of suicide or self-harm
  • Received previous treatment with plasma exchange for GBS
  • Any diagnosis of a variant of GBS
  • Have a history of anaphylaxis or severe systemic response to immunoglobulin
  • Documented, clinically significant, pre-existing polyneuropathy from another cause
  • Clinically significant intercurrent illness, medical condition, or medical history
  • History of chronic use of or medication
  • Active alcohol, drug, or substance abuse
  • Females who are pregnant, breast feeding, or unable or unwilling to use highly effective methods of throughout the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Open Label Treatment Arm

    One (1) dose of ANX005, 75 mg/kg, will be administered IV. IVIg, 0.4 g/kg, will be administered for 5 consecutive Days.

    Drug: ANX005 · Drug: Intravenous immunoglobulin

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of ANX005 when administered in combination with IVIg: incidence of TEAEs, SAEs, AE's

    As measured by incidence of TEAEs, SAEs, AE's related to ANX005, SAE's related to ANX005, Grade 3 or higher AEs, Grade 3 or higher AEs related to ANX005, AEs leading to study or treatment discontinuation.

    Time frame: 6 months

Secondary outcomes

  1. Pharmacokinetics of ANX005 when administered in combination with IVIg

    As measured by ANX005 serum concentrations

    Time frame: 3 months

  2. Pharmacodynamics of ANX005 when administered in combination with IVIg

    As measured by CH50 and C1q serum concentrations

    Time frame: 4 months

  3. Values and change from baseline in Guillain-Barré Syndrome Disability Score (GBS-DS) by visit

    The 6-point Guillain-Barré Syndrme Disability Score (GBS-DS) is a widely accepted and easily obtainable scoring system used to assess functional status of GBS subjects. The score is as follows: 0 = Healthy, 1 = Minor symptoms and capable of running, 2 = Able to walk independently 10 meters or more but unable to run, 3=Able to walk more than 10 meters across an open space with help, 4 = Bedridden or chair bound, 5 = Needing mechanical ventilation, 6 = death

    Time frame: 6 months

07

Study locations

2 sites
  • National Institute of Neurosciences and Hospital
    Dhaka, Bangladesh
  • Aarhus University Hospital
    Aarhus, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in May 2021, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2019
First posted
Jul 29, 2019
StartActual
Jan 29, 2020
Primary completionActual
May 19, 2021
CompletionActual
May 19, 2021
Last update
Aug 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04035135
Lead sponsor
Annexon, Inc.
Responsible party
Sponsor
First posted
Jul 29, 2019
Start date
Jan 29, 2020
Primary completion
May 19, 2021
Completion
May 19, 2021
Last update
Aug 11, 2021

Study contacts

Henk-André Kroon, MD, MBA
study director · Annexon, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tanruprubart · Immunoglobulins, Intravenous

Start the discussion